Benchmark Issues Pessimistic Forecast for Agilon Health (NYSE:AGL) Stock Price

Agilon Health (NYSE:AGL) had its target price cut by equities research analysts at Benchmark from $4.00 to $1.50 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Benchmark’s target price would indicate a potential upside of 73.41% from the company’s current price.

A number of other research firms also recently issued reports on AGL. Barclays boosted their target price on shares of Agilon Health from $2.00 to $3.00 and gave the company an “underweight” rating in a report on Thursday, May 8th. Wells Fargo & Company decreased their price target on Agilon Health from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, May 13th. The Goldman Sachs Group lifted their target price on Agilon Health from $2.50 to $5.00 and gave the stock a “neutral” rating in a research report on Thursday, May 8th. JMP Securities reiterated a “market perform” rating on shares of Agilon Health in a research note on Monday, April 28th. Finally, Sanford C. Bernstein upgraded shares of Agilon Health from a “market perform” rating to an “outperform” rating and upped their target price for the company from $3.30 to $8.50 in a research note on Tuesday, April 8th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Agilon Health presently has an average rating of “Hold” and a consensus target price of $4.07.

Agilon Health Price Performance

NYSE:AGL opened at $0.87 on Wednesday. The firm has a market cap of $358.47 million, a PE ratio of -1.12 and a beta of 0.14. The firm has a 50 day simple moving average of $2.10 and a 200-day simple moving average of $3.17. Agilon Health has a 1-year low of $0.71 and a 1-year high of $6.08.

Agilon Health (NYSE:AGL) last released its earnings results on Monday, August 4th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.14). The firm had revenue of $1.39 billion during the quarter, compared to analysts’ expectations of $1.47 billion. Agilon Health had a negative return on equity of 66.76% and a negative net margin of 5.35%. The firm’s revenue was down 5.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.07) earnings per share. As a group, sell-side analysts expect that Agilon Health will post -0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agilon Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Humankind Investments LLC bought a new stake in Agilon Health in the fourth quarter worth about $30,000. Raymond James Financial Inc. purchased a new position in Agilon Health in the 4th quarter worth about $33,000. Cerity Partners LLC purchased a new position in Agilon Health in the 4th quarter worth about $34,000. 111 Capital purchased a new stake in Agilon Health during the second quarter valued at about $36,000. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Agilon Health by 244.9% during the first quarter. Nisa Investment Advisors LLC now owns 9,553 shares of the company’s stock valued at $41,000 after acquiring an additional 6,783 shares during the period.

Agilon Health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.